Loading
A phase 2 trial of Endoscopic resection in Oesophageal squamous cell carcinoma, run by Shanghai Zhongshan Hospital, not yet recruiting.
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer is a phase 2 interventional study registered as NCT06599775 by Shanghai Zhongshan Hospital, with 42 participants planned, started 2024-10 and due to reach its primary completion in 2026-10. Interventions recorded: Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection. Conditions recorded: Resectable Esophageal Squamous Cell Carcinoma.
Linked to the technology Endoscopic resection because the registry's title names it ("endoscopic resection") and Oesophageal squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares Endoscopic resection (EMR / ESD), Oesophageal squamous cell carcinoma and the tag pipeline.
Shares Adebrelimab, Carboplatin and the tag pipeline.
Shares Adebrelimab, Carboplatin and the tag pipeline.
Shares Adebrelimab, Carboplatin and the tag pipeline.
Shares Adebrelimab, Carboplatin and the tag pipeline.
Shares Endoscopic resection (EMR / ESD) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma and the tag pipeline.